Beverly Hills, CA-based biotech Capricor Therapeutics revealed today final data from its clinical trial evaluating stem cell therapy CAP-1002 for patients in advanced stages of Duchenne muscular dystrophy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2023,